Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.7355 EUR 2.65% Market Closed
Market Cap: 498.9m EUR
Have any thoughts about
Pharming Group NV?
Write Note

P/FCFE
Price to FCFE

-11.6
Current
-11.9
Median
27.3
Industry
Higher than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-11.6
=
Market Cap
493.6m EUR
/
FCFE
-44.8m USD
All Countries
Close
Market Cap P/FCFE
NL
Pharming Group NV
AEX:PHARM
493.6m EUR -11.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 193 097.1
US
Abbvie Inc
NYSE:ABBV
299.8B USD 12
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD -89.2
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 11.5
US
Epizyme Inc
F:EPE
94.1B EUR -429.7
AU
CSL Ltd
ASX:CSL
137.3B AUD 80.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 26
US
Seagen Inc
F:SGT
39.3B EUR -59.1
NL
argenx SE
XBRU:ARGX
34B EUR -108.2
 
NL
Pharming Group NV
AEX:PHARM
Average P/FCFE: 31.4
Negative Multiple: -11.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 193 097.1
US
Abbvie Inc
NYSE:ABBV
12
US
Amgen Inc
NASDAQ:AMGN
26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -89.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -429.7
AU
CSL Ltd
ASX:CSL
80.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.2

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More